Matthew Kulke, MD
Zoltan Kohn Professor of Medicine
Boston University School of Medicine
Dept of Medicine

MD, University of California, San Francisco
MMS/MMSc, Harvard Medical School




Matthew Kulke MD is the Chief of Hematology/Oncology, Co-Director of the BU/BMC Cancer Center and Zoltan Kohn Professor at the Boston University School of Medicine. Dr. Kulke is an internationally recognized for his work in the field of neuroendocrine tumors. He has led or co-led both early and late stage clinical trials leading to the development of telotristat ethyl, temozolomide, sunitinib, everolimus and peptide receptor radiotherapy for the treatment of neuroendocrine tumors. His work has additionally included characterization of neuroendocrine tumors at the molecular level, and has resulted in over 200 peer-reviewed publications.

Dr. Kulke received his undergraduate degree in molecular biology from Princeton University magna cum laude, and his medical degree with a thesis honors award from the University of California, San Francisco School of Medicine where he also was a Regent’s scholar and received a research training fellowship from the Howard Hughes Medical Institute. He performed his internship and residency at Brigham and Women’s Hospital, a medical oncology fellowship at Dana-Farber Cancer Institute, and received a Masters in Medical Science Degree from Harvard Medical School.

Prior to coming to Boston University he was a Professor of Medicine at Harvard Medical School and Director of the Neuroendocrine Tumor Program at Dana-Farber Cancer Institute. He has served as principal investigator for NCI cooperative group trials in both neuroendocrine tumors and pancreatic cancer, served as chair of the National Cancer Institute’s Neuroendocrine Tumor Clinical Trial Task Force, chair of the North American Neuroendocrine Tumor Society, and chair of the National Comprehensive Cancer Network’s neuroendocrine tumor guidelines committee.

Section Chief
Boston Medical Center
Medicine
Hematology & Medical Oncology

Co-Director
Boston University
BU-BMC Cancer Center


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research



2017 Neuroendocrine Tumor Research Foundation: Lauren Erb Award for Contributions to Neuroendocrine Tumor Research
2011 Dana-Farber Cancer Institute: Kenneth E Schwarz Center Compassionate Care Giver Award
2010 Dana-Farber Cancer Institute: Lee Nadler Extra Mile Award
2009 University of Pittsburgh School of Medicine: Ruth Brufsky Award for Excellence in Clinical Research on Pancreatic Cancer Research
2008 Dana-Farber Cancer Institute: Kenneth E Schwarz Center Compassionate Care Giver Award
2003 Dana-Farber Cancer Institute: George Canellos Award for Contributions to Clinical Research
1999-2001 Dana-Farber Cancer Institute: Discovery Fellowship
1998-1999 American Society of Clinical Oncology: Young Investigator Award
1992 UC San Francisco School of Medicine: Thesis Honors Award



SWOG Clinical Trials
03/01/2019 - 02/28/2025 (PI)
Oregon Health and Science University NIH-NCI

PEN-221: A Phase 1/2a, open-label multicenter study to assess the safety, tolerability, pharma…
08/19/2019 - 08/18/2022 (PI)
Tarveda Therapeutics, Inc.

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy…
07/02/2019 - 07/01/2022 (PI)
Incyte Corporation

SWOG - Clinical Trials Initiative
02/28/2009 - 02/28/2021 (PI)
South West Oncology Group NIH-NCI

SWOG Master Agreement
02/26/2014 - 02/25/2021 (PI)
Oregon Health and Science University NIH-NCI

Multidimensional IO markers of Response and Resistance to Checkpoint Inhibition
09/13/2018 - 09/12/2020 (PI)
Bristol-Myers

Neuroendocrine tumors for single cell RNAseq
10/01/2018 - 09/01/2020 (PI)
Dana Farber


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Du C, da Silva A, Morales-Oyarvide V, Dias Costa A, Kozak MM, Dunne RF, Rubinson DA, Perez K, Masugi Y, Hamada T, Brais LK, Yuan C, Babic A, Ducar MD, Thorner AR, Aguirre A, Kulke MH, Ng K, Clancy TE, Findeis-Hosey JJ, Chang DT, Hornick JL, Fuchs CS, Ogino S, Koong AC, Hezel AF, Wolpin BM, Nowak JA. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2020 Aug; 29(8):1586-1595. PMID: 32467349
     
  2. Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. J Gastrointest Cancer. 2020 Mar 07. PMID: 32146619
     
  3. Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020 Sep; 47(10):2372-2382. PMID: 32123969
     
  4. Rosenblum RE, Harris CK, Baeg KJ, Starr JA, Brais LK, Stashek KM, Ward SC, Katona BW, Clancy TE, Wisnivesky JP, Kulke MH, Metz DC, Kim MK, Chan JA. Predictors of Recurrence and Survival in Patients With Surgically Resected Pancreatic Neuroendocrine Tumors. Pancreas. 2020 02; 49(2):249-254. PMID: 32011530
     
  5. Jalbert JJ, Casciano R, Meng J, Brais LK, Pulgar SJ, Berthon A, Dinet J, Kulke MH. Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center. Oncologist. 2020 Apr; 25(4):e644-e650. PMID: 31999024
     
  6. Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2019 Nov; 30(11):1846. PMID: 31987097
     
  7. Fisher MD, Pulgar S, Kulke MH, Mirakhur B, Miller PJ, Walker MS, Schwartzberg LS. Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database. J Gastrointest Cancer. 2019 Dec; 50(4):816-823. PMID: 30121904; DOI: 10.1007/s12029-018-0160-x;
     
  8. Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2019 11 01; 30(11):1846. PMID: 31407000
     
  9. Hudgens S, Ramage J, Kulke M, Bergsland E, Anthony L, Caplin M, Öberg K, Pavel M, Gable J, Banks P, Yang QM, Lapuerta P. Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. J Patient Rep Outcomes. 2019 Oct 26; 3(1):64. PMID: 31655936
     
  10. Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC, Bernstein BE, Shivdasani RA. Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019 Oct; 25(10):1627.View Related Profiles. PMID: 31501535
     
Showing 10 of 208 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 208 publications over 23 distinct years, with a maximum of 24 publications in 2017

YearPublications
19971
19991
20001
20014
20023
20035
20045
20056
200614
200710
200811
200914
20108
201113
20129
201314
201410
20159
201614
201724
201814
201912
20206

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Gastrointestinal Oncology
Neuroendocrine Tumors
Novel Therapeutics
Biomarkers
Genetics
Contact for Mentoring:

820 Harrison Ave
Boston MA 02118
Google Map


Kulke's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department